Parkside Financial Bank & Trust’s Syndax Pharmaceuticals SNDX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35	Closed	-$539	–	2791
2025 Q3	$539	Buy	+35	New	+$458	﹤0.01%	2550
2025 Q2	–	Sell	-40	Closed	-$492	–	2979
2025 Q1	$492	Buy	+40	New	+$564	﹤0.01%	2402

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Parkside Financial Bank & Trust's SNDX Position: Q4 2025 in Review

Parkside Financial Bank & Trust sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 35 shares — an estimated $539 sold.

Parkside Financial Bank & Trust first reported a position in SNDX in Q1 2025 and held it in 2 quarters. The position peaked at $539 in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Parkside Financial Bank & Trust reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Parkside Financial Bank & Trust sold 35 Syndax Pharmaceuticals shares in Q4 2025, an estimated $539.
Parkside Financial Bank & Trust first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 2 quarters.
Parkside Financial Bank & Trust's Syndax Pharmaceuticals position peaked at $539 in Q3 2025.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q4 2025, filed 13 Feb 2026.